Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
4.450
+0.020 (0.45%)
Sep 8, 2026, 11:50 AM EDT - Market open
Minerva Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
212.48M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 80.62M |
| Coherus Oncology | 50.94M |
| Precision BioSciences | 45.06M |
| Voyager Therapeutics | 34.46M |
| Alpha Cognition | 15.26M |
| Armata Pharmaceuticals | 5.54M |
| Oramed Pharmaceuticals | 2.00M |
NERV News
- 11 days ago - Minerva Neurosciences to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 23 days ago - Minerva upgraded to Buy from Hold at Jefferies - TheFly
- 4 weeks ago - Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates - GlobeNewsWire
- 4 weeks ago - Minerva Neurosciences Earnings release: Q2 2026 - Filings
- 4 weeks ago - Minerva Neurosciences Quarterly report: Q2 2026 - Filings
- 3 months ago - Minerva Neurosciences Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 3 months ago - Minerva Neurosciences Transcript: AGM 2026 - Transcripts
- 3 months ago - Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs - GlobeNewsWire